The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PKTX | -24.55% | -93.36% | -41.85% | +108% |
| S&P | +12.9% | +73.65% | +11.66% | +487% |
Protokinetix, Inc. is a research and development stage biotechnology company engaged in the scientific medical research of anti-aging glycoproteins. The company was founded by Grant Young on December 23, 1999 and is headquartered in Dalton, OH.
No news articles found for ProtoKinetix.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$12.64K | 16.4% |
| Market Cap | $2.14M | -45.2% |
| Net Income | -$84.91K | -0.4% |
| EBITDA | -$72.27K | -4.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.61K | -89.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -78.62% | 1.8% |
| Return On Invested Capital | -623.28% | 128.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.91K | 90.0% |
| Operating Free Cash Flow | -$3.91K | 90.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 9.35 | 13.15 | 8.88 | 6.55 | -29.63% |
| Price to Tangible Book Value | -45.30 | -35.24 | -32.94 | -14.47 | -79.21% |
| Enterprise Value to EBITDA | -41.30 | -52.66 | -39.39 | -29.63 | -47.21% |
| Return on Equity | -93.6% | -96.0% | -101.6% | -117.2% | 29.97% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
